Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Further Reading

Researchers identify role of tumor-infiltrating B-cells in melanoma progression, resistance to therapy

Researchers identify role of tumor-infiltrating B-cells in melanoma progression, resistance to therapy

New medication shows potential to reduce fracture risk in women with osteoporosis

New medication shows potential to reduce fracture risk in women with osteoporosis

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Pfizer receives FDA approval for new therapy to treat adults and children with AML

Reducing inflammation without lowering cholesterol significantly lowers rate of recurrent cardiovascular events

Reducing inflammation without lowering cholesterol significantly lowers rate of recurrent cardiovascular events

Anti-inflammatory therapy reduces incidence of lung cancer

Anti-inflammatory therapy reduces incidence of lung cancer

Drug reduces inflammation to lower cardiovascular disease and lung cancer risk

Drug reduces inflammation to lower cardiovascular disease and lung cancer risk

UC San Diego researchers receive $18.2 million grant for B cell cancer clinical trial

UC San Diego researchers receive $18.2 million grant for B cell cancer clinical trial

Tumor irradiation may prolong survival of NSCLC patients undergoing novel chemotherapy formulation

Tumor irradiation may prolong survival of NSCLC patients undergoing novel chemotherapy formulation

Study provides better understanding of how estrogen regulates gene expression

Study provides better understanding of how estrogen regulates gene expression

Einstein researchers receive three NIH grants to protect against deadly viruses

Einstein researchers receive three NIH grants to protect against deadly viruses

Omeros’ OMS721 receives orphan drug designation from FDA for treatment of IgA nephropathy

Omeros’ OMS721 receives orphan drug designation from FDA for treatment of IgA nephropathy

Southampton researchers find new approach to reverse treatment resistance in lymphoma patients

Southampton researchers find new approach to reverse treatment resistance in lymphoma patients

Novel therapy decreases incidence of bleeding by 87% in hemophilia A patients with inhibitors

Novel therapy decreases incidence of bleeding by 87% in hemophilia A patients with inhibitors

Scientists develop novel DNA-based strategy to protect against broad array of influenza viruses

Scientists develop novel DNA-based strategy to protect against broad array of influenza viruses

New monoclonal antibody shows efficacy in chronic migraine patients with medication overuse

New monoclonal antibody shows efficacy in chronic migraine patients with medication overuse

Research details how lymphoma cells acquire resistance to targeted therapy

Research details how lymphoma cells acquire resistance to targeted therapy

Antibody-based theranostic agent shows promise for identifying and treating pancreatic tumors

Antibody-based theranostic agent shows promise for identifying and treating pancreatic tumors

Novartis announces data revealing efficacy of new monoclonal antibody therapy in preventing migraine

Novartis announces data revealing efficacy of new monoclonal antibody therapy in preventing migraine

Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

Novartis, Bristol-Myers Squibb collaborate to examine combination therapies for metastatic colorectal cancer

Novartis, Bristol-Myers Squibb collaborate to examine combination therapies for metastatic colorectal cancer